title: Niclosamide inhibition of STAT3 synergizes with erlotinib in human colon cancer.
abstract: Niclosamide, an anthelmintic drug approved by the US Food and Drug Administration against cestodes, is used to treat tapeworm infection. In this study, we show that niclosamide can potentially inhibit signal transducer and activator of transcription 3 (STAT3) in colon cancer cell lines. Combined inhibition of epidermal growth factor receptor and STAT3 by erlotinib and niclosamide synergistically induces apoptosis and antiproliferation in colon cancer cell lines. Our findings suggest that erlotinib and niclosamide combination provides an effective therapeutic approach to improving the prognosis of colon cancer.
authors.affiliation: Chemical Biology Research Center, School of Pharmaceutical Sciences.
authors.forename: Lingyi
authors.initials: L
authors.lastname: Shi
authors.affiliation: Chemical Biology Research Center, School of Pharmaceutical Sciences.
authors.forename: Hailun
authors.initials: H
authors.lastname: Zheng
authors.affiliation: Department of Coloproctology, The Second Affiliated Hospital and Yuying Children's Hospital.
authors.forename: Wanle
authors.initials: W
authors.lastname: Hu
authors.affiliation: Department of Coloproctology, The Second Affiliated Hospital and Yuying Children's Hospital.
authors.forename: Bin
authors.initials: B
authors.lastname: Zhou
authors.affiliation: Department of Oncological Surgery, The First Affiliated Hospital, Wenzhou Medical University, Wenzhou, People's Republic of China.
authors.forename: Xuanxuan
authors.initials: X
authors.lastname: Dai
authors.affiliation: Department of Oncological Surgery, The First Affiliated Hospital, Wenzhou Medical University, Wenzhou, People's Republic of China.
authors.forename: Yi
authors.initials: Y
authors.lastname: Zhang
authors.affiliation: Chemical Biology Research Center, School of Pharmaceutical Sciences.
authors.forename: Zhiguo
authors.initials: Z
authors.lastname: Liu
authors.affiliation: Chemical Biology Research Center, School of Pharmaceutical Sciences.
authors.forename: Xiaoping
authors.initials: X
authors.lastname: Wu
authors.affiliation: Chemical Biology Research Center, School of Pharmaceutical Sciences.
authors.forename: Chengguang
authors.initials: C
authors.lastname: Zhao
authors.affiliation: Chemical Biology Research Center, School of Pharmaceutical Sciences.
authors.forename: Guang
authors.initials: G
authors.lastname: Liang
keywords: EGFR; STAT3; colon cancer; erlotinib; niclosamide